Single-group Phase II study (n=15) testing two doses of oral psilocybin (15 mg then 25 mg, two sessions ~2 weeks apart) with preparatory and integration psychotherapy in US military Veterans with PTSD.
This single-group, interventional Phase II study will enroll 15 US military Veterans with DSM-5 PTSD to evaluate safety and efficacy of psilocybin-assisted psychotherapy.
Participants receive preparatory therapy (up to 6–8 hours across up to 4 meetings), two psilocybin sessions (15 mg then 25 mg about two weeks apart; each session ≈8 hours, two facilitators), and post-session integration visits with follow-up to 6 months.
Two-dose psilocybin with preparatory and integration therapy sessions (single-group design).
15 mg first session; 25 mg second session; each session ~8 hours; facilitated by two trained session facilitators.